eEFFECTOR Therapeutics, Inc. - רווח נקי למניה ב-12 החודשים האחרונים EFTR

eFFECTOR Therapeutics (EFTR) possesses high scientific authority in developing selective inhibitors for lung cancer therapy. The annual percentage growth of EPS TTM reflects current dynamics, with the value holding at -623.40. However, the business is currently winding down operations due to a funding shortage, while global conflicts are blocking logistics and the execution of critical international clinical trials.

The specifics of the eFFECTOR Therapeutics (EFTR) operating model are reflected in the annual dynamics of the EPS TTM metric. This indicator captures the percentage change in trailing twelve-month net income per share, with calculations based on a comparison of current results against the same period last year. For a company in the stage of program liquidation and liquidity shortages, such fluctuations reflect the capital burn rate. An increase in this metric does not signify efficiency here, but merely records the pace of loss reduction.